OncologyOnline.net

Oncology Xagena

Xagena Mappa
Medical Meeting
Cardiobase
Farmaexplorer.it

Treatment with Nazartinib ( EGF816 ), a third generation epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor ( TKI ), provided durable responses in adult patients with EGFR-mutated non ...


Although some patients with Platinum-pretreated metastatic urothelial cancer ( mUC ) demonstrated good responses to Nivolumab monotherapy, the response rate and survival were higher with combined Nivo ...


The pivotal phase 3 KEYNOTE-426 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Axitinib ( Inlyta ), tyrosine kinase inhibitor, met both primary endpoints of ...


The results from an interim analysis of KEYNOTE-057, a phase 2 trial evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bla ...


The U.S. Food and Drug Administration ( FDA ) has approved an expanded label for Keytruda, an anti-PD-1 therapy, in combination with Pemetrexed ( Alimta ) and Platinum chemotherapy for the first-line ...


Updated preliminary clinical data from an ongoing phase I dose escalation and expansion study evaluating the safety and efficacy of the combination of Monalizumab, a first-in-class monoclonal antibody ...


Radical metastasectomy followed by observation is a commonly used strategy in selected patients with metastatic renal cell carcinoma ( mRCC ). RESORT was the largest prospective study that assesse ...


Dacomitinib is an irreversible, pan-epidermal growth factor receptor ( HER ) inhibitor. The goal of a study was to evaluate the frontline therapy in advanced penile squamous cell carcinoma ( PSCC ), ...


Nivolumab ( Opdivo ) has shown efficacy and acceptable safety in 2 open-label, multicenter studies ( CheckMate 032 and 275 ) and is approved for patients with metastatic urothelial carcinoma ( mUC ) ...


The results from the phase 3 PROSPER trial in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CRPC ) were announced . The results show that the use of Enzalutamide ( Xtand ...


The main aim of adjuvant therapy, which is given after an apparently successful primary cancer treatment, is to reduce the risk of local and distant metastatic disease relapse owing to residual breast ...


Researchers at Columbia University Medical Center ( CUMC ) have discovered that the fusion of two adjacent genes can cause cancer by kicking mitochondria into overdrive and increasing the amount of f ...


Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor prognosis and survival. More recently, while new ...


Antibodies that block programmed death 1 ( PD-1 ) receptor and its ligand, PD-L1, have shown durable responses in multiple cancer types. PD-1 has been shown to be upregulated in hepatitis C virus ( ...


Updated data from the advanced non-small cell lung cancer ( NSCLC ) patient cohort of the ongoing phase 1/2 ECHO-202 trial, evaluating Epacadostat, a selective IDO1 enzyme inhibitor, in combination wi ...